Buscar
Immix Biopharma Inc
IMMXAñadir a la lista de seguimiento
10.340USD
+0.510+5.19%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
547.51MCap. mercado
PérdidaP/E TTM
Más Datos de Immix Biopharma Inc Compañía
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Información de Immix Biopharma Inc
Símbolo de cotizaciónIMMX
Nombre de la empresaImmix Biopharma Inc
Fecha de salida a bolsaDec 16, 2021
Director ejecutivoRachman (Ilya)
Número de empleados18
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 16
Dirección11400 West Olympic Blvd.
CiudadLOS ANGELES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal90064
Teléfono18889581084
Sitio Webhttps://immixbio.com/
Símbolo de cotizaciónIMMX
Fecha de salida a bolsaDec 16, 2021
Director ejecutivoRachman (Ilya)
Ejecutivos de Immix Biopharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immix Biopharma Inc?
Los cinco principales accionistas de Immix Biopharma Inc son: Mr. Jason Hsu, Ph.D.
¿Cuántas instituciones poseen acciones de Immix Biopharma Inc (IMMX)?
A fecha de 2026Q1, 105 instituciones poseen acciones de Immix Biopharma Inc, con un valor de mercado combinado de aproximadamente 24.89M, lo que representa el 45.75% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 18028804.00.